NCT01592292View on ClinicalTrials.gov

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy

CompletedOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Rituximab

Rituximab as per physician's discretion.

DRUG

Adalimumab

Adalimumab as per physician's discretion.

DRUG

Etanercept

Etanercept as per physician's discretion.

DRUG

Infliximab

Infliximab as per physician's discretion.

Trial Locations (15)

10380

Gyeonggi-do

41931

Daegu

42472

Daegu

44033

Ulsan

48108

Busan

61469

Gwangju

63241

Jeju Special Self-Governing Province

302-799

Daejeon

561-712

Jeollabuk-do

05030

Seoul

06273

Seoul

130-702

Seoul

134-722

Seoul

150-713

Seoul

442-723

Suwon

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01592292 - An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy | Biotech Hunter | Biotech Hunter